What is Wellbutrin XL?
Wellbutrin XL is Bausch Health’s extended-release bupropion, approved in August 2003 for major depressive disorder and for preventing seasonal affective disorder in adults. Like Wellbutrin SR, it carries a dose-related seizure risk and can raise blood pressure, but it releases bupropion over a full day and is the only Wellbutrin form approved for seasonal depression.1
Approved products and generic therapeutic-equivalence ratings are listed in the FDA Orange Book.3
For seasonal affective disorder, three placebo-controlled trials enrolled adults with a history of autumn-winter depression.1
At the end of treatment, the share of patients who stayed free of a depressive episode was 81.4%, 87.2% and 84.0% with Wellbutrin XL, compared with 69.7%, 78.7% and 69.0% on placebo.1
Seizure incidence has not been formally evaluated for Wellbutrin XL itself; sustained-release bupropion within the usual range carried about a 0.1% incidence.
In those seasonal trials, mean daily doses ranged close to the usual target, and treatment lasted about 4 to 6 months for most patients.1
The tablets are creamy-white to pale yellow and round, printed in black with “Wellbutrin XL” and the strength.
Wellbutrin XL is one of the depression medicines; its depression efficacy rests on trials of the immediate-release formulation.1
